PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28821194
OWN - NLM
STAT- MEDLINE
DA  - 20170819
DCOM- 20170906
LR  - 20170906
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 148
IP  - 3
DP  - 2017 Sep 01
TI  - Primary Benign and Malignant Thyroid Neoplasms With Signet Ring Cells: Cytologic,
      Histologic, and Molecular Features.
PG  - 251-258
LID - 10.1093/ajcp/aqx074 [doi]
AB  - Objectives: Signet ring cells (SRCs) can be seen in a variety of thyroid tumors
      and can pose a diagnostic pitfall on cytology. This study describes the
      cytologic, histomorphologic, and molecular aspects of a cohort of primary thyroid
      tumors with SRCs. Methods: A search was performed of the Massachusetts General
      Hospital and Brigham and Women's Hospital (Boston, MA) pathology archives for the
      keywords thyroid, signet, and signet ring features between 2000 and 2014. Seven
      thyroidectomy specimens with corresponding thyroid fine-needle aspiration (FNA)
      were obtained. Cytology and histopathology slides were evaluated. Molecular
      analysis was performed using anchored multiplex polymerase chain reaction (AMP). 
      Results: The cohort consisted of four follicular adenomas (FAs), two noninvasive 
      follicular thyroid neoplasms with papillary-like nuclear features (NIFTPs), and
      one secretory carcinoma (SC). The FNA diagnoses were atypia of undetermined
      significance (n = 3), suspicious for follicular neoplasm (n = 3), and suspicious 
      for malignancy (n = 1). Molecular analyses revealed PTEN and FGFR3 mutations in
      an FA and NIFTP, respectively, and an ETV6-NTRK3 fusion in a case of primary
      thyroid gland SC. Conclusions: Our study demonstrates the range of thyroid tumors
      with SRCs. While most thyroid tumors with SRCs are benign, primary thyroid SC
      should also be considered in the differential diagnosis.
FAU - Farhat, Nada A
AU  - Farhat NA
AD  - Massachusetts General Hospital, Boston.
AD  - Harvard Medical School, Boston, MA.
FAU - Onenerk, Ayse M
AU  - Onenerk AM
AD  - Massachusetts General Hospital, Boston.
AD  - Harvard Medical School, Boston, MA.
FAU - Krane, Jeffrey F
AU  - Krane JF
AD  - Harvard Medical School, Boston, MA.
AD  - Brigham and Women's Hospital, Boston, MA.
FAU - Dias-Santagata, Dora
AU  - Dias-Santagata D
AD  - Massachusetts General Hospital, Boston.
AD  - Harvard Medical School, Boston, MA.
FAU - Sadow, Peter M
AU  - Sadow PM
AD  - Massachusetts General Hospital, Boston.
AD  - Harvard Medical School, Boston, MA.
FAU - Faquin, William C
AU  - Faquin WC
AD  - Massachusetts General Hospital, Boston.
AD  - Harvard Medical School, Boston, MA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - EC 2.7.10.1 (FGFR3 protein, human)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 3)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
SB  - AIM
SB  - IM
MH  - Adenocarcinoma, Follicular/metabolism/*pathology/surgery
MH  - Adenoma/metabolism/*pathology/surgery
MH  - Adolescent
MH  - Aged
MH  - Aged, 80 and over
MH  - Biopsy, Fine-Needle
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - PTEN Phosphohydrolase/metabolism
MH  - Receptor, Fibroblast Growth Factor, Type 3/metabolism
MH  - Thyroid Neoplasms/metabolism/*pathology/surgery
MH  - Thyroidectomy
OTO - NOTNLM
OT  - Cytopathology
OT  - Fine-needle aspiration
OT  - Molecular testing
OT  - Secretory carcinoma of thyroid
OT  - Signet ring cells
OT  - Thyroid
EDAT- 2017/08/20 06:00
MHDA- 2017/09/07 06:00
CRDT- 2017/08/20 06:00
AID - 4057633 [pii]
AID - 10.1093/ajcp/aqx074 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2017 Sep 1;148(3):251-258. doi: 10.1093/ajcp/aqx074.